Nörofibromatozis Tip1’li Olgularda NF1 Geni Varyant Spektrumu: Tek Merkez Deneyimi

Öz

Giriş ve Amaç: Nörofibromatozis tip 1 başlıca cafe au lait lekeleri, Lisch nodülleri ve nörofibromlarla karakterize otozomal dominant kalıtımlı bir rasopatidir. Bu çalışmada amacımız, NF1 ön tanısıyla başvuran hastaların genotipik verilerini sunmaktır. Gereç ve Yöntemler: 2018 Haziran–2022 Haziran tarihleri arasında yaş ortalaması 8,1 yaş (2 ay-28 yaş aralığında) olan 22 olgu NF1 ön tanısıyla değerlendirildi. Hastalara NF1 geni dizi analizi yapıldı. Bulgular: NF1 geni dizi analizi yöntemiyle tanı oranı %90,9 idi. 16 farklı NF1 geni varyantından 13 (%81,25) 'ü patojenik/muhtemel patojenik iken, 3 (%18,75)'ü ise klinik önemi bilinmeyen varyantlardı. Sonuç: NF1 ön tanısıyla başvuran hastalardaki genetik tanı oranı ve klinik bulguları literatür verileri eşliğinde tartışıldı. 4 yeni NF1 geni varyantı saptandı.

Anahtar Kelimeler

• Nörofibromatozis tip 1
• Yeni nesil DNA dizileme
• NF1 geni
• yeni varyantlar

NF1 Gene Variant Spectrum with Neurofibromatosis Type 1 Patients: Single Center Experience

Öz

Objective: Neurofibromatosis type 1 is an autosomal dominant inherited rasopathy mainly characterized by cafe au lait macules, Lisch nodules and neurofibromas. In this study, our aim is to present the genotypic data of patients evaluated with a pre-diagnosis of NF1. Materials and Methods: Between June 2018 and June 2022, 22 cases with a mean age of 8.1 years (range 2 months to 28 years) were evaluated with a pre-diagnosis of NF1. NF1 gene sequence analysis was performed on the patients. Results: The diagnosis rate was 90.9% by NF1 gene sequence analysis. Out of a total of 16 NF1 gene variations, 13 (81,25%) were pathogenic/likely pathogenic, while 3 (18,75%) were variants of uncertaine significance. Conclusion: The rate of genetic diagnosis and clinical findings in patients presenting with a pre-diagnosis of NF1 were discussed in the light of literature data. 4 novel NF1 gene variants were identified.

Anahtar Kelimeler

• Neurofibromatosis type 1
• Next generation DNA sequencing
• NF1 gene
• novel variants

Kaynakça

1. Referans1. Stella, A, Lastella, P, et al., Clinical presentation and genetic analyses of neurofibromatosis type 1 in independent patients with monoallelic double de novo closely spaced mutations in the NF1 gene, Human Mutation, 2022
2. Referans2. Üstün, C, Arslan, M, Nörofibromatozis Tip 1 Tanısı ile İzlenen Hastaların Klinik Özellikleri: Tek Merkez Deneyimi, Türkiye Çocuk Hastalıkları Dergisi, 2022, 1–5.
3. Referans 3. Legius E, Messiaen L, et al., International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC), Huson SM, Evans DG, Plotkin SR. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genetics in Medicine, 2021, 23(8), 1506-1513.
4. Referans4. Richards, S, Aziz, N, et al., Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, Genetics in Medicine, 2015, 17(5), 405–423.
5. Referans5. N, Abdel-Aziz, N, Y, El-Kamah, G, et al., Mutational spectrum of NF1 gene in 24 unrelated Egyptian families with neurofibromatosis type 1. Moleculer Genetics& Genomic Medicine, 2021, 9(12), e1631.
6. Referans6. Torres, Nupan, MM, Velez, Van, Meerbeke, A, et al., Cognitive and Behavioral Disorders in Children with Neurofibromatosis Type 1. Frontiers in Pediatrics, 2017, 5, 227.
7. Referans7. Acosta, MT, Bearden CE, et al., The learning disabilities network (LeaDNet): using neurofibromatosis type 1 (NF1) as a paradigm for translational research. American Journal of Medical Genetics, Part A, 2012, 158A, 2225-2232.
8. Referans8. Gresham, FM, MacMillan, DL, Bocian, KM, Learning disabilities, low achievement, and mild mental retardation: more a like than different?, Journal of Learning Disabilities, 1996, 29(6), 570–581.

9. Referans9. Gonca Kaçar, A, Kılınc Oktay, B, et al. Neurofibromatosis Type 1 in Children: A Single-Center Experience. Turkish Archives Pediatrics, 2021, 56(4), 339-343.
10. Referans10. Napolitano, F, Dell'Aquila, M, et al, Genotype-Phenotype Correlations in Neurofibromatosis Type 1: Identification of Novel and Recurrent NF1 Gene Variants and Correlations with Neurocognitive Phenotype, Genes (Basel), 2022, 13(7), 1130.
11. Referans11. Valero, M, C, Martin, Y, et al, A highly sensitive genetic protocol to detect NF1 mutations, The Journal of Molecular Diagnostics, 2011, 13(2), 113–122.
12. Referans12. Peltonen, S, Kallionpää, R, A, et al. Pediatric malignancies in neurofibromatosis type 1: a population‐based cohort study, International Journal of Cancer. 2019, 145, 2926-2932.
13. Referans13. Anderson, J, L, Gutmann, D, H, Neurofibromatosis type 1, Handbook of clinical neurology, 2015, 132, 75–86.
14. Referans14. Ly, K, I, Blakeley, J, O, The Diagnosis and Management of Neurofibromatosis Type 1. The Medical Clinics of North America, 2019, 103(6), 1035–1054.